Today: 1 May 2026
SGX stock edges up as Nasdaq dual-listing rules move to Feb 8 deadline; Singapore Exchange earnings next
12 January 2026
1 min read

SGX stock edges up as Nasdaq dual-listing rules move to Feb 8 deadline; Singapore Exchange earnings next

Singapore, Jan 12, 2026, 15:21 SGT — Regular session

  • Shares of Singapore Exchange climbed roughly 0.5% in afternoon trading, following a solid gain to close last week.
  • Regulators have opened consultations on rule changes aimed at simplifying the SGX-Nasdaq dual listing process, seeking feedback by Feb. 8
  • SGX flagged a boost in trading activity and a pickup in securities turnover as the year winds down

Shares of Singapore Exchange Ltd (S68) climbed 0.5% to S$17.59 by 3:10 p.m. Singapore time Monday, amid investor interest in new efforts to simplify dual listings in Singapore and the U.S.

The bourse operator is at the heart of Singapore’s push to revive its market. A genuine boost in listings or trading volume would be significant, since exchanges rake in fees whenever more money and securities move through.

The Monetary Authority of Singapore is pushing for legislative and regulatory tweaks to back an SGX-Nasdaq “dual-listing bridge,” including permitting a single prospectus for a simultaneous IPO listing. MAS also suggested retail investors get engaged earlier, right after IPO documents are filed. a.siasset.com

SGX shares closed Friday at S$17.51, rising roughly 1.2%, just ahead of the fresh consultation details hitting the market, The Business Times reported.

SGX flagged a pickup in market activity heading into year-end. Securities turnover jumped 29% year-on-year in December, hitting S$25.8 billion. The daily average securities value for 2025 also climbed 21% to roughly S$1.5 billion — marking the highest level since 2010, the bourse operator’s report showed.

The consultation process sets the foundation for a new Global Listing Board, designed to ease the path for companies seeking to list shares on both SGX and Nasdaq. Essentially, this involves synchronizing timelines and disclosure requirements so issuers don’t have to juggle two separate rulebooks.

But several moving parts introduce downside risk for investors. MAS has put forward “safe harbour” provisions—legal shields if the rules are met—but the framework’s success still depends heavily on market conditions and deal execution, which can shift fast. SIAS chief executive David Gerald believes the proposals might “bring the best of both markets” to Singapore investors. Lawyer Robson Lee cautioned that uptake will hinge on the market “sustaining the upswing momentum” and having enough issue managers and distribution networks. The Straits Times

Traders are eyeing if the proposed eligibility criteria will shrink the candidate pool and if retail allocation rules will reshape deal structures. For SGX, the stakes go beyond fresh listings to include follow-on trading and clearing volume.

SGX will release its first-half FY2026 results before markets open on Feb. 5. CEO Loh Boon Chye and CFO Daniel Koh are set to address investors at 9:00 a.m. Singapore time.

Stock Market Today

  • Seaport Therapeutics Upsizes IPO to $255M, CEO Highlights New Biotech Pathway
    May 1, 2026, 2:02 PM EDT. Seaport Therapeutics raised $254.9 million in an upsized Nasdaq IPO, exceeding initial $180 million estimates. CEO Daphne Zohar highlighted a shift from traditional M&A (mergers and acquisitions) to public offerings, reflecting confidence in developing and marketing their depression drug pipeline independently. The company may raise an additional $38.2 million through underwriters' option. Zohar pointed to industry changes where biotech firms are now focusing on advancing medicines directly to patients, citing success stories like Karuna Therapeutics and Intra-Cellular Therapies. Seaport's board recently welcomed Sharon Mates, who led Intra-Cellular to a $1.5 billion drug launch before its J&J acquisition. This IPO signals renewals in the biotech public market despite recent Big Pharma dealmaking.

Latest article

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

1 May 2026
The Dow Jones Industrial Average fell 78.72 points to 49,573.42 by midday Friday, reversing an early rally as tariff concerns weighed on gains from Apple and other strong earnings reports. President Donald Trump announced a 25% tariff on EU-made cars and trucks starting next week. Apple reported quarterly revenue of $111.2 billion, up 17% year over year. Oil prices dropped after Iran sent a new negotiation proposal.
US Stock Market Today: Why the S&P 500 and Nasdaq Are Hitting Fresh Highs

US Stock Market Today: Why the S&P 500 and Nasdaq Are Hitting Fresh Highs

1 May 2026
The S&P 500 rose 0.48% and the Nasdaq 0.96% to record highs Friday, while the Dow slipped 0.11%. Apple shares climbed after reporting its strongest quarterly sales growth in over four years. Atlassian and other software stocks rallied on strong cloud demand. Exxon and Chevron beat profit estimates but cited pressure from Middle East conflict and volatile oil prices.
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

1 May 2026
Recursion Pharmaceuticals said founder and board chair Chris Gibson will not seek re-election at the June 17 annual meeting, months after stepping down as CEO. The company reports first-quarter results May 6, with investors watching for updates on cash, clinical progress, and its AI drug platform. Recursion last reported $753.9 million in cash and narrowed its quarterly net loss. Gibson will remain chair until his term ends.
Hawaiian Electric stock jumps 8% into the weekend — here’s what matters before HE trades again
Previous Story

Hawaiian Electric stock jumps 8% into the weekend — here’s what matters before HE trades again

Yangzijiang Financial (YF8) stock ticks up in Singapore as U.S. CPI and Fed tensions loom
Next Story

Yangzijiang Financial (YF8) stock ticks up in Singapore as U.S. CPI and Fed tensions loom

Go toTop